Department of Neurosciences, Cleveland Clinic, Cleveland, OH, 44195, USA.
Proteomics. 2019 Aug;19(16):e1800335. doi: 10.1002/pmic.201800335. Epub 2019 Jun 21.
Multiple sclerosis (MS) is a chronic inflammatory demyelinating and neurodegenerative disease of the central nervous system (CNS). The cause of MS is unknown, with no effective therapies available to halt the progressive neurological disability. Development of new and improvement of existing therapeutic strategies therefore require a better understanding of MS pathogenesis, especially during the progressive phase of the disease. This can be achieved through development of biomarkers that can help to identify disease pathophysiology and monitor disease progression. Proteomics is a powerful and promising tool to accelerate biomarker detection and contribute to novel therapeutics. In this review, an overview of how proteomic technology using CNS tissues and biofluids from MS patients has provided important clues to the pathogenesis of MS is provided. Current publications, pitfalls, as well as directions of future research involving proteomic approaches to understand the pathogenesis of MS are discussed.
多发性硬化症（MS）是一种中枢神经系统（CNS）的慢性炎症性脱髓鞘和神经退行性疾病。MS 的病因尚不清楚，也没有有效的治疗方法可以阻止进行性神经功能障碍。因此，需要开发新的治疗策略并改进现有的治疗策略，这就需要更好地了解 MS 的发病机制，特别是在疾病的进行性阶段。这可以通过开发能够帮助识别疾病病理生理学和监测疾病进展的生物标志物来实现。蛋白质组学是一种强大且有前途的工具，可以加速生物标志物的检测并有助于开发新的治疗方法。在这篇综述中，提供了一个概述，介绍了如何使用 MS 患者的中枢神经系统组织和生物体液的蛋白质组学技术为 MS 的发病机制提供重要线索。讨论了当前的出版物、陷阱以及涉及蛋白质组学方法来理解 MS 发病机制的未来研究方向。
